EphA2 as a target for ovarian cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1179-1187

  Landen, Charles N ^a   Kinch, Michael S ^b   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Antibody therapy; Cancer; Eph receptor; EphA2; Ephrin; SiRNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTINEOPLASTIC AGENT; DIOLEOYLPHOSPHATIDYLCHOLINE; EPHRIN RECEPTOR A2; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TAXANE DERIVATIVE; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CANCER TISSUE; DISEASE COURSE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, EPHA2;

EID: 28844447276     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1179     Document Type: Review

References (67)

1. GALE NW, HOLLAND SJ, VALENZUELA DM et al.: Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron (1996) 17(1):9-19.
2. HIMANEN JP, RAJASHANKAR KR, LACKMANN M, COWAN CA, HENKEMEYER M, NIKOLOV DB: Crystal structure of an Eph receptor-ephrin complex. Nature (2001) 414(6866):933-938.
3. LIU W, JUNG YD, AHMAD SA et al.: Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer. Br. J. Cancer 2004) 90(8):1620-1626.
4. WU Q, SUO Z, RISBERG B, KARLSSON MG, VILLMAN K, NESLAND JM: Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol. Res. (2004) 10(1):26-33.
5. BATLLE E, BACANI J, BEGTHEL H et al.: EphB receptor activity suppresses colorectal cancer progression. Nature (2005) 435(7045):1126-1130.
6. CHEN J, NACHABAH A, SCHERER C et al.: Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion. Oncogene (1996) 12(5):979-988.
7. ZELINSKI DP, ZANTEK ND, STEWART JC, IRIZARRY AR, KINCH MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. (2001) 61(5):2301-2306.
8. EASTY DJ, HILL SP, HSU MY et al.: Up-regulation of ephrin-A1 during melanoma progression. Int. J. Cancer (1999) 84(5):494-501.
9. OGAWA K, PASQUALINI R, LINDBERG RA, KAIN R, FREEMAN AL, PASQUALE EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene (2000) 19(52):6043-6052.
10. STRAUME O, AKSLEN LA: Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am. J. Pathol. (2002) 160(3):1009-1019.
11. MIYAZAKI T, KATO H, FUKUCHI M, NAKAJIMA M, KUWANO H: EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer (2003) 103(5):657-663.
12. SAITO T, MASUDA N, MIYAZAKI T et al.: Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol. Rep. (2004) 11(3):605-611.
13. KATAOKA H, IGARASHI H, KANAMORI M et al.: Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. (2004) 95(2):136-141.
14. KINCH MS, MOORE MB, HARPOLE DH, JR: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. (2003) 9(2):613-618.
15. THAKER PH, DEAVERS M, CELESTINO J et al.: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. (2004) 10(15):5145-5150.
16. WU D, SUO Z, KRISTENSEN GB et al.: Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol. Oncol. (2004) 94(2):312-319.
17. WALKER-DANIELS J, COFFMAN K, AZIMI M et al.: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate (1999) 41(4):275-280.
18. TATSUMI T, HERREM CJ, OLSON WC et al.: Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. (2003) 63(15):4481-4499.
19. LU M, MILLER KD, GOKMEN-POLAR Y, JENG MH, KINCH MS: EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. (2003) 63(12):3425-3429.
20. HU M, CARLES-KINCH KL, ZELINSKI DP, KINCH MS: EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells. Mol. Cancer Res. (2004) 2(10):533-540.
21. SEFTOR RE: Electrophoretic analysis of proteins associated with tumor cell invasion. ELectrophoresis (1994) 15(3-4):454-462.
22. SANDERS RJ, MAINIERO F, GIANCOTTI FG: The role of integrins in tumorigenesis and metastasis. Cancer Invest. (1998) 16(5):329-344.
23. ZANTEK ND, AZIMI M, FEDOR-CHAIKEN M, WANG B, BRACKENBURY R, KINCH MS: E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. (1999) 10(9):629-638.
24. MIAO H, BURNETT E, KINCH M, SIMON E, WANG B: Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. (2000) 2(2):62-69.
25. CARLES-KINCH K, KILPATRICK KE, STEWART JC, KINCH MS: Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. (2002) 62(10):2840-2847.
26. KOOLPE M, DAIL M, PASQUALE EB: An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem. (2002) 277(49):46974-46979.
27. PANDEY A, LAZAR DF, SALTIEL AR, DIXIT VM: Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J. Biol. Chem. (1994) 269(48):30154-30157.
28. PANDEY A, DUAN H, DIXIT VM: Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase. J. Biol. Chem. (1995) 270(33):19201-19204.
29. KIKAWA KD, VIDALE DR, VAN ETTEN RL, KINCH MS: Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J. Biol. Chem. 2002) 277(42):39274-39279.
30. WALKER-DANIELS J, RIESE DJ, 2nd, KINCH MS: c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol. Cancer Res. (2002) 1(1):79-87.
31. PRATT RL, KINCH MS: Activation of the EphA2 tyrosine kinase stimulates the MAP/ ERK kinase signaling cascade. Oncogene (2002) 21(50):7690-7699.
32. BARTLEY TD, HUNT RW, WELCHER AA et al.: B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature (1994) 368(6471):558-560.
33. KINCH MS, BURRIDGE K: Altered adhesions in ras-transformed breast epithelial cells. Biochem. Soc. Trans. (1995) 23(3):446-450.
34. BIRCHMEIER W, HULSKEN J, BEHRENS J: E-cadherin as an invasion suppressor. Ciba Found. Symp. (1995) 189:124-136; discussion 136-141, 174-176.
35. BERX G, VAN ROY F: The E-cadherin/ catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001) 3(5):289-293.
36. STEIN E, LANE AA, CERRETTI DP et al.: Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. (1998) 12(5):667-678,
37. CHIARUGI P, TADDEI ML, SCHIAVONE N et al.: LMW-PTP is a positive regulator of tumor onset and growth. Oncogene (2004) 23(22):3905-3914.
38. BRANTLEY DM, CHENG N, THOMPSON EJ, LIN Q, BREKKEN RA, THORPE PE et al.: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 21(46):7011-7026.
39. CHENG N, BRANTLEY DM, LIU H et al.: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. (2002) 1(1):2-11.
40. POTLA L, BOGHAERT ER, ARMELLINO D, FROST P, DAMLE NK: Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett. (2002) 175(2):187-195.
41. NOBLITT LW, BANGARI DS, SHUKLA S, MOHAMMED S, MITTAL SK: Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther. (2005) 12(1):46-53.
42. BRANTLEY-SIEDERS DM, CAUGHRON J, HICKS D, POZZI A, RUIZ JC, CHEN J: EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell Sci. (2004) 117(Pt 10):2037-2049.
43. CHENG N, BRANTLEY D, FANG WB et al.: Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia (2003) 5(5):445-456.
44. DOBRZANSKI P, HUNTER K, JONES-BOLIN S et al.: Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. (2004) 64(3):910-919.
45. HANAHAN D: Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 315(6015):115-122.
46. NOBLITT LW, BANGARI DS, SHUKLA S et al.: Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. (2004) 11(11):757-766.
47. FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806-811.
48. ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
49. RYTHER RC, FLYNT AS, PHILLIPS JA, PATTON JG: siRNA therapeutics: big potential from small RNAs. Gene Ther. (2005) 12(1):5-11.
50. HANNON GJ, ROSSI JJ: Unlocking the potential of the human genome with RNA interference. Nature (2004) 431(7006):371-378.
51. MCCAFFREY AP, MEUSE L, PHAM TT, CONKLIN DS, HANNON GJ, KAY MA: RNA interference in adult mice. Nature (2002) 418(6893):38-39.
52. LEWIS DL, HAGSTROM JE, LOOMIS AG, WOLFF JA, HERWEIJER H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. (2002) 32(1):107-108.
53. KLEIN C, BOCK CT, WEDEMEYER H et al.: Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 125(1):9-18.
54. XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. (2002) 20(10):1006-1010.
55. DEVROE E, SILVER PA: Therapeutic potential of retroviral RNAi vectors. Expert Opin. Biol. Ther. (2004) 4(3):319-327.
56. DORN G, PATEL S, WOTHERSPOON G et al.: siRNA relieves chronic neuropathic pain. Nucleic Acids Res. (2004) 32(5):e49.
57. SCHIFFELERS RM, XU J, STORM G, WOODLE MC, SCARIA PV: Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum. (2005) 52(4):1314-1318.
58. BITKO V, MUSIYENKO A, SHULYAYEVA O, BARIK S: Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. (2005) 11(1):50-55.
59. TOLENTINO MJ, BRUCKER AJ, FOSNOT J et al.: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina (2004) 24(1):132-138.
60. DUXBURY MS, ITO H, ZINNER MJ, ASHLEY SW, WHANG EE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene (2004) 23(7):1448-1456.
61. LANDEN CN, Jr, CHAVEZ-REYES A, BUCANA C et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. (2005) 65(15):6910-6918.
62. THAKER PH, YAZICI S, NILSSON MB et al.: Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin. Cancer Res. (2005) 11(13):4923-4933.
63. LANDEN C, COFFMAN K, HAN L et al.: Anti-vascular therapy of ovarian cancer with an EphA2-agonistic monoclonal antibody. In: Proceedings of the American Association of Cancer Research (2005):1702.
64. MIAO H, WEI BR, PEEHL DM et al.: Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. (2001) 3(5):527-530.
65. AOKI M, YAMASHITA T, TOHYAMA M: EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. (2004) 279(31):32643-32650.
66. MANIOTIS AJ, FOLBERG R, HESS A et al.: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. (1999) 155(3):739-752.
67. SOOD AK, SEFTOR EA, FLETCHER MS et al.: Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. (2001) 158(4):1279-1288.